

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 FORIS renamed to SOFIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 Capplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:35:51 ON 08 NOV 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 20:36:06 ON 08 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 NOV 2007 HIGHEST RN 952647-77-7

DICTIONARY FILE UPDATES: 7 NOV 2007 HIGHEST RN 952647-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524204a.str



```

chain nodes :
11 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-12 3-15 4-16 8-13 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
3-15 4-16 5-7 6-9 7-8 8-9 8-13
exact bonds :
2-12 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:O,CN,X,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:Atom 15:CLASS 16:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,CN,X,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 20:36:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2526 TO ITERATE

79.2% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

13 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 47506 TO 53534
PROJECTED ANSWERS: 85 TO 571

L2 13 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 20:36:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 49437 TO ITERATE

100.0% PROCESSED 49437 ITERATIONS
SEARCH TIME: 00.00.01

191 ANSWERS

L3 191 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY
172.10

SESSION
172.31

FILE 'CAPLUS' ENTERED AT 20:36:37 ON 08 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Nov 2007 VOL 147 ISS 20
FILE LAST UPDATED: 7 Nov 2007 (20071107/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 4 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:817587 CAPLUS

DOCUMENT NUMBER: 147:211880

TITLE: Preparation of imidazopyridine derivatives as protein kinase inhibitors for the treatment of diabetes, obesity, dementia, cancer, and inflammation

INVENTOR(S): Lee, Seung Chul; Choi, Jin Seok; Oh, Jung Hoon; Park, Boonsaeng; Kim, Yong Eun; Lee, Jun Hee; Shin, Dongkyu; Kim, Cheol Min; Hyun, Young-Lan; Lee, Cheol Soon; Cho, Joong-Myung; Ro, Seonggu

PATENT ASSIGNEE(S): Crystalgenomics, Inc., S. Korea

SOURCE: PCT Int. Appl., 157pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2007083978 | A1 | 20070726 | WO 2007-KR393 | 20070123 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: KR 2006-6834 A 20060123
US 2006-846411P P 20060921

OTHER SOURCE(S): MARPAT 147:211880

GI



AB Title compds. I [wherein R1 = OH, halo, alkyl, etc.; R2 = H, (un)substituted alkyl, aryl, etc.; R3 - R5 = H, (un)substituted alkyl, cycloalkyl, etc.; R2 and R3 may link together to form a ring] and pharmaceutically acceptable salts, hydrates, solvates or isomers thereof were prepared as protein kinase inhibitors. For instance, successive nitro reduction of 4-methyl-3-nitropyridin-2-amine, cyclocondensation of the resultant diamine with benzoic acid to imidazopyridine, oxidation of the Me group with KMnO₄ and esterification in methanol, hydrolysis of the obtained Me ester, and EDC-mediated coupling with 4-acetylphenethylamine led to amide II. This product showed inhibition of glycogen synthase kinase-3 (GSK-3) with an IC₅₀ of 0.02 μM. Inhibitory activity of representative I against other protein kinases, including aurora kinase A, extracellular signal-regulated kinase 1 (ERK-1), cyclin-dependent kinase 2 (CDK-2), c-Jun N-terminal kinase 1 (JNK-1), pyruvate dehydrogenase kinase 1 (PDK-1), kinase insert domain protein receptor (KDR) and p38 mitogen-activated protein kinase (MAPK), was also demonstrated. Therefore, the invented compds. and pharmaceutical compns. are useful for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation.


| | | | |
|----|--------------|--------------|--------------|
| IT | 944741-02-0P | 944741-03-1P | 944741-04-2P |
| | 944741-05-3P | 944742-41-0P | 944742-92-1P |
| | 944743-61-7P | 944743-62-8P | 944745-47-5P |
| | 944745-74-8P | 944745-79-3P | |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridine derivs. as protein kinase inhibitors for treatment of diabetes, obesity, dementia, cancer, and inflammation)


RN 944741-02-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, N-[4-(benzoylamino)phenyl]-6-bromo-2-phenyl- (CA INDEX NAME)




RN 944741-03-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-phenyl- (CA INDEX NAME)




RN 944741-04-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-phenyl-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 944741-05-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-chloro-N-[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]-2-phenyl- (CA INDEX NAME)




RN 944742-41-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]-2-(3-furanyl)- (CA INDEX NAME)




RN 944742-92-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(3-thienyl)- (CA INDEX NAME)




RN 944743-61-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 944743-62-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-chloro-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 944745-47-5 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-(3-methoxyphenyl)-N-(4-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 944745-74-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-(3-fluorophenyl)-N-(4-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 944745-79-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-(4-ethoxy-6-methyl-3-pyridinyl)-2-(3-fluorophenyl)- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:996177 CAPLUS
 DOCUMENT NUMBER: 141:424193
 TITLE: Imidazo- and thiazolopyridines as JAK3 kinase

INVENTOR(S): inhibitors
 Hemmerling, Martin; Klingstedt, Tomas
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|------------------|------------|
| WO 2004099204 | A1 | 20041118 | WO 2004-SE694 | 20040506 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004236144 | A1 | 20041118 | AU 2004-236144 | 20040506 |
| CA 2524624 | A1 | 20041118 | CA 2004-2524624 | 20040506 |
| EP 1625126 | A1 | 20060215 | EP 2004-731525 | 20040506 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004010081 | A | 20060516 | BR 2004-10081 | 20040506 |
| CN 1784402 | A | 20060607 | CN 2004-80012617 | 20040506 |
| JP 2006525997 | T | 20061116 | JP 2006-508045 | 20040506 |
| MX 2005PA12025 | A | 20060203 | MX 2005-PA12025 | 20051108 |
| US 2006287355 | A1 | 20061221 | US 2005-556228 | 20051109 |
| PRIORITY APPLN. INFO.: | | | SE 2003-1373 | A 20030304 |
| | | | WO 2004-SE694 | W 20040506 |
| OTHER SOURCE(S): | | MARPAT 141:424193 | | |
| GI | | | | |



AB Title compds. I [Y = NH, S, O; Ar = (un)substituted Ph; R1 =
 (un)substituted Ph, 5-7-membered heteroarom.] were prepared for use as JAK3
 kinase inhibitors with IC50 < 25 μ M. Thus, 7-hydroxy-2-
 methylthiothiazolo[5,4-b]pyridine-6-carboxylic acid was converted to its
 amide, aminated with 2-EtC6H4NH2, oxidized to the sulfone in two steps,
 and treated with MeONa to give I [Y = S, Ar = 2-EtC6H4, R1 = OMe].
 IT 796088-60-3P 796088-61-4P 796088-63-6P
 796088-64-7P 796088-65-8P 796088-66-9P
 796088-67-0P 796088-68-1P 796088-69-2P
 796088-70-5P 796088-71-6P 796088-72-7P
 796088-73-8P 796088-74-9P 796088-75-0P
 796088-76-1P 796088-77-2P 796088-78-3P
 796088-79-4P 796088-80-7P 796088-81-8P
 796088-82-9P 796088-83-0P 796088-84-1P
 796088-85-2P 796088-86-3P 796088-87-4P
 796088-88-5P 796088-89-6P 796088-90-9P


796088-91-0P 796088-92-1P 796088-93-2P
 796088-94-3P 796088-95-4P 796088-96-5P
 796088-97-6P 796088-98-7P 796088-99-8P
 796089-00-4P 796089-01-5P 796089-02-6P
 796089-03-7P 796089-04-8P 796089-05-9P
 796089-06-0P 796089-07-1P 796089-08-2P
 796089-09-3P 796089-10-6P 796089-11-7P
 796089-12-8P 796089-13-9P 796089-14-0P
 796089-15-1P 796089-16-2P 796089-17-3P
 796089-18-4P 796089-19-5P 796089-20-8P
 796089-21-9P 796089-22-0P 796089-23-1P
 796089-24-2P 796089-25-3P 796089-26-4P
 796089-27-5P 796089-28-6P 796089-29-7P
 796089-30-0P 796089-31-1P 796089-32-2P
 796089-33-3P 796089-34-4P 796089-35-5P
 796089-36-6P 796089-37-7P 796089-38-8P
 796089-39-9P 796089-40-2P 796089-41-3P
 796089-42-4P 796089-43-5P 796089-44-6P
 796089-45-7P 796089-46-8P 796089-47-9P
 796089-48-0P 796089-49-1P 796089-50-4P
 796089-58-2P 796089-59-3P 796089-66-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of imidazo- and thiazolopyridines as JAK3 kinase inhibitors)


RN 796088-60-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-
 (hydroxymethyl)phenyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)



RN 796088-61-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-
 hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-63-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-(dimethylamino)phenyl]-7-[(2-
 ethylphenyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 796088-62-5


CMF C23 H24 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 796088-64-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-65-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-66-9 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(3,4-dihydroxyphenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 796088-67-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(3-cyanophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-68-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(4-cyanophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-69-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-70-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(3,4-difluorophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-71-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(3-chloro-4-hydroxyphenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-72-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 796088-73-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-74-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-(acetylamino)phenyl]-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-75-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-76-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(2-hydroxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 796088-77-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-78-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 796088-79-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-80-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-81-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-82-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-83-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethoxy]phenyl]-7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 796088-84-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-85-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-86-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxypropyl)amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-87-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxypropyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 796088-88-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 796088-89-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 796088-90-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796088-91-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796088-92-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—OH

RN 796088-93-2 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796088-94-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-95-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI)
 (CA INDEX NAME)




RN 796088-96-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796088-97-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796088-98-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-


hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796088-99-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-00-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-01-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-


hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-02-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidinyl)methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-03-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[1-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-04-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[4-(methylsulfonyl)phenyl]methyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-05-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 796089-06-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[2-(hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 796089-07-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 796089-08-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 796089-09-3 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 796089-10-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-11-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-12-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-13-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-14-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-15-1 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-16-2 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[(2-hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-17-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-18-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-19-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidiny]methyl]phenyl]amino]-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 796089-20-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[1-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-21-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[4-(methylsulfonyl)phenyl]methyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-22-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-(hydroxypropyl)amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-23-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 796089-24-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-25-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-26-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-27-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-28-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-29-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-30-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-31-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-32-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-33-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[(2-hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-34-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 796089-35-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-36-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidiny]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-37-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxypropyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-38-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxy-1-methylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-39-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-40-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-41-3 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-42-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-pyridinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-43-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 796089-44-6 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 796089-45-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-46-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(2R)-2-(hydroxymethyl)-1-phenylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-47-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-48-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-49-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidinyl)methyl]phenyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-50-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[1-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-58-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-59-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-66-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 796088-60-3

CMF C22 H21 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:162689 CAPLUS

DOCUMENT NUMBER: 140:199327

TITLE: Preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis

INVENTOR(S): Johansson, Henrik; Lawitz, Karolina; Nikitidis, Grigorios; Sjoe, Peter; Storm, Peter

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004016611 | A1 | 20040226 | WO 2003-SE1279 | 20030813 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2495511 | A1 | 20040226 | CA 2003-2495511 | 20030813 |
| AU 2003251272 | A1 | 20040303 | AU 2003-251272 | 20030813 |
| EP 1539759 | A1 | 20050615 | EP 2003-788216 | 20030813 |
| EP 1539759 | B1 | 20070815 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | |

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | |
|------------------------|-------------------|----------|----------------|------------|
| BR 2003013461 | A | 20050705 | BR 2003-13461 | 20030813 |
| CN 1684964 | A | 20051019 | CN 2003-823193 | 20030813 |
| JP 2006503010 | T | 20060126 | JP 2004-529004 | 20030813 |
| NZ 538156 | A | 20060929 | NZ 2003-538156 | 20030813 |
| AT 370138 | T | 20070915 | AT 2003-788216 | 20030813 |
| ZA 2005000887 | A | 20060222 | ZA 2005-887 | 20050131 |
| MX 2005PA01581 | A | 20050425 | MX 2005-PA1581 | 20050209 |
| US 2005261333 | A1 | 20051124 | US 2005-524204 | 20050210 |
| NO 2005001265 | A | 20050512 | NO 2005-1265 | 20050311 |
| PRIORITY APPLN. INFO.: | | | SE 2002-2462 | A 20020814 |
| OTHER SOURCE(S): | MARPAT 140:199327 | | WO 2003-SE1279 | W 20030813 |
| GI | | | | |



I



II


AB The use of imidazopyridines (shown as I; variables defined below; e.g. II trifluoroacetate) and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compds. I, together with processes for their preparation, compns. containing them and their use in therapy are also disclosed.

For I: R3 = halogen, CN, C1-3-alkyl or C1-3-alkoxy; Ar = Ph, a 5-6-membered heteroarom. ring or an indole ring, said heteroarom. ring incorporating 1 to 3 O, N and S; R1 = H, halogen, CN, C1-6-alkyl, NO2, SO2Me, C1-6-alkynyl, CH2OH, OR2, (CH2)nNR4R5 or Ph (un)substituted by NH2; m = 1-2 and when m = 2, each R1 may be selected independently; n = 0 or 1; R10 = H, halogen, CN, C1-4-alkyl, C1-4-alkoxy, NR14R15 or a group -X-Y-Z (X = O, S, a bond or NR16 wherein R16 = H or C1-4-alkyl; Y = C1-4-alkyl or a bond; Z = Ph, naphthyl or a 5- or 6-membered heteroarom. ring, a 5- or 6-membered saturated heterocyclic ring containing 1-2 heteroatoms = O, N and S, or


C3-6-cycloalkyl); addnl. details are given in the claims. Methods of preparation are claimed and >250 example preps. of I are included. For example, II was prepared by condensing 4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)aniline with 4-methoxybenzenesulfonyl chloride in pyridine. In another example, 5-bromo-2,3-diaminopyridine was cyclized with 4-hydroxybenzaldehyde in DMF in the presence of iron(III) chloride hexahydrate to give 65% 4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenol. In another example, N-benzyl-5-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine bis(trifluoroacetate) was prepared in 3 steps starting with cyclization of 2,3-diamino-5-bromopyridine with 6-chloronicotinic acid in the presence of polyphosphoric acid (53%) followed by chlorination

using POC13 to give 44% 6-bromo-2-(6-chloropyridin-3-yl)-3H-imidazo[4,5-b]pyridine followed by condensation with benzylamine (51%). Compds. of Examples 1 to 278 gave IC50 values for inhibition of Itk activity of <25 μ M, e.g. 0.26 μ M for II.


- IT 662116-65-6P, 6,7-Dichloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662116-73-6P, N-Benzyl-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-74-7P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-75-8P 662116-81-6P, 6-Chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine trifluoroacetate 662116-89-4P, 2-[Benzyl[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol 662116-93-0P, N-Benzyl-6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662117-13-7P, 7-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile 662117-18-2P, 6,7-Dichloro-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]-1H-imidazo[4,5-b]pyridine 662117-21-7P, 2-Amino-5-(6-chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)phenol 662117-23-9P, 4-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-nitrophenol 662117-24-0P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-nitrophenol 662117-35-3P, 2-(4-Aminophenyl)-6-chloro-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine 662117-41-1P, 6-Bromo-7-methyl-2-(4-nitrophenyl)-1H-imidazo[4,5-b]pyridine 662117-42-2P, 4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)aniline
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis)
- RN 662116-65-6 CAPLUS
- CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



- RN 662116-73-6 CAPLUS
- CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



- RN 662116-74-7 CAPLUS
- CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-75-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 662116-73-6


CMF C25 H26 Cl N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 662116-81-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 662116-80-5


CMF C26 H28 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662116-89-4 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 662116-93-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 662117-13-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carbonitrile, 7-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-18-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 662117-21-7 CAPLUS
 CN Phenol, 2-amino-5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI)
 (CA INDEX NAME)




RN 662117-23-9 CAPLUS
 CN Phenol, 4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-nitro- (9CI)
 (CA INDEX NAME)




RN 662117-24-0 CAPLUS
 CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-nitro- (9CI)
 (CA INDEX NAME)




RN 662117-35-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-7-amine, 2-(4-aminophenyl)-6-chloro-N-phenyl-
 (9CI) (CA INDEX NAME)



RN 662117-41-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6-bromo-7-methyl-2-(4-nitrophenyl)- (9CI) (CA
 INDEX NAME)



RN 662117-42-2 CAPLUS
 CN Benzenamine, 4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI)
 (CA INDEX NAME)



IT 662116-68-9P, 6-Chloro-N-(2-methoxyphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
 662116-69-0P, 2-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenol 662116-70-3P,
 6-Chloro-N-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
 662116-72-5P, 6-Chloro-N-cyclopentyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine


662116-80-5P, 6-Chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
662116-84-9P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-7-amine 662116-85-0P,
[3-[6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]methanol 662116-86-1P,
6-Chloro-N-(2-fluorophenyl)-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridin-7-amine 662116-87-2P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-phenyl-1H-imidazo[4,5-b]pyridin-7-amine
662116-88-3P, 6-Chloro-N-(3-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
662116-90-7P, 2-[Benzyl[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol
bis(trifluoroacetate) 662116-91-8P, 2-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol
662116-92-9P, 2-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol bis(trifluoroacetate)
662116-94-1P, 6-Chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
662116-95-2P, 7-(Benzylthio)-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridine 662116-96-3P,
7-(Benzylthio)-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridine bis(trifluoroacetate) 662116-97-4P,
6-Chloro-N-[4-(methylsulfonyl)phenyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
662116-98-5P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[4-(4-morpholinyl)phenyl]-1H-imidazo[4,5-b]pyridin-7-amine
662116-99-6P, N'-[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-N,N-diethyl-1,4-benzenediamine
662117-00-2P, N-[4-[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]acetamide 662117-01-3P, N-[4-[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]acetamide bis(trifluoroacetate) 662117-02-4P,
6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenoxy-1H-imidazo[4,5-b]pyridine 662117-04-6P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[2-(1-pyrrolidinyl)ethoxy]-1H-imidazo[4,5-b]pyridine 662117-05-7P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-[2-(morpholin-4-yl)ethyl]-3H-imidazo[4,5-b]pyridin-7-amine 662117-07-9P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-(1-phenylethyl)-3H-imidazo[4,5-b]pyridin-7-amine
662117-12-6P, 2-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6,7-dicarbonitrile 662117-14-8P,
7-Anilino-2-[4-[2-[(2-methoxyethyl)(methyl)amino]ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile 662117-19-3P,
5-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]aniline 662117-25-1P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[[[(2R)-pyrrolidin-2-yl)methyl]amino]phenol
662117-26-2P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[[[(2R)-pyrrolidin-2-yl)methyl]amino]phenol bis(trifluoroacetate)
662117-28-4P, [5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(morpholin-4-yl)ethoxy]phenyl][[(2R)-pyrrolidin-2-yl)methyl]amine
662117-30-8P, 4-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-N'-[2-(morpholin-4-yl)ethyl]benzene-1,2-diamine 662117-31-9P,
[5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-(4-methylpiperazin-1-yl)phenyl]amine 662117-33-1P, 6,7-Dichloro-2-[4-(4-morpholinyl)phenyl]-1H-imidazo[4,5-b]pyridine 662117-34-2P,
[5-(6,7-Dichloro-3H-imidazo[4,5-b]pyridin-2-yl)-2-(morpholin-4-yl)phenyl]amine 662117-38-6P, N-[4-(6,7-Dichloro-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-[2-(morpholin-4-yl)ethyl]amine
662117-40-0P, 6-Bromo-7-methyl-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662117-43-3P,
N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyanobenzenesulfonamide 662117-44-4P 662117-45-5P,
N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-

cyanobenzenesulfonamide 662117-46-6P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-
 cyanobenzenesulfonamide bis(trifluoroacetate) 662117-47-7P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]quinoline-8-
 sulfonamide 662117-48-8P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-
 b]pyridin-2-yl)phenyl]quinoline-8-sulfonamide bis(trifluoroacetate)
 662117-49-9P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-
 yl)phenyl]-4-methoxybenzenesulfonamide 662117-50-2P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-
 methoxybenzenesulfonamide trifluoroacetate 662117-51-3P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-
 cyanoethoxy)benzenesulfonamide 662117-52-4P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-
 cyanoethoxy)benzenesulfonamide trifluoroacetate 662117-54-6P,
 N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl-1H-
 imidazole-4-sulfonamide trifluoroacetate 662117-55-7P,
 N-[4-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-
 methoxybenzenesulfonamide 662117-56-8P, N-[4-(6,7-Dichloro-1H-
 imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide
 trifluoroacetate 662117-58-0P, 6-Chloro-2-[4-[[2-(morpholin-4-
 yl)ethyl]amino]phenyl]-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine
 662117-59-1P, 6-Chloro-7-methoxy-2-[4-[2-(morpholin-4-
 yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662117-64-8P,
 6-Chloro-2-[4-[di(3-cyanobenzyl)amino]phenyl]-7-methoxy-3H-imidazo[4,5-
 b]pyridine 662117-67-1P, 3-[[[4-(6-Chloro-7-methoxy-1H-
 imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]benzonitrile
 662117-68-2P, 3-[[[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-
 2-yl)phenyl]amino]methyl]benzonitrile trifluoroacetate
 662117-69-3P, N-[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-
 yl)phenyl]-4-cyanobenzenesulfonamide 662117-70-6P,
 N-[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-
 cyanobenzenesulfonamide trifluoroacetate 662117-71-7P,
 6-Chloro-7-methoxy-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-imidazo[4,5-
 b]pyridine 662117-72-8P, 6-Chloro-7-methoxy-2-[4-[2-(piperidin-1-
 yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine bis(trifluoroacetate)
 662117-91-1P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-
 yl)phenyl]-1-methyl-1H-imidazole-4-sulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of imidazopyridines as Itk kinase inhibitors
 for use against asthma and allergic rhinitis)


RN 662116-68-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-methoxyphenyl)-2-[4-[2-(4-
 morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-69-0 CAPLUS

CN Phenol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-
 b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 662116-70-3 CAPLUS

CN 3-Pyrrolidinamine, N-[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-1-(methanesulfonyl)- (9CI) (CA INDEX NAME)




RN 662116-72-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-cyclopentyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-80-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-84-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 662116-85-0 CAPLUS

CN Benzenemethanol, 3-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 662116-86-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-fluorophenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-87-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 662116-88-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(3-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-90-7 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl](phenylmethyl)amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-89-4


CMF C27 H30 Cl N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662116-91-8 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 662116-92-9 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-91-8


CMF C20 H24 Cl N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662116-94-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 662116-95-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 662116-96-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[(phenylmethyl)thio]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-95-2


CMF C25 H25 Cl N4 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662116-97-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-[4-(methylsulfonyl)phenyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-98-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 662116-99-6 CAPLUS

CN 1,4-Benzenediamine, N'-[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 662117-00-2 CAPLUS

CN Acetamide, N-[4-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-01-3 CAPLUS

CN Acetamide, N-[4-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 662117-00-2

CMF C26 H27 Cl N6 O3




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 662117-02-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenoxy- (9CI) (CA INDEX NAME)




RN 662117-04-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 662117-05-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 662117-07-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 662117-12-6 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6,7-dicarbonitrile, 2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 662117-14-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine-6-carbonitrile, 2-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 662117-19-3 CAPLUS
 CN Benzenamine, 5-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 662117-25-1 CAPLUS
 CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[[2-(2-pyrrolidinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 662117-26-2 CAPLUS


CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[[(2R)-2-pyrrolidinylmethyl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-25-1

CMF C18 H20 Cl N5 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 662117-28-4 CAPLUS


CN 2-Pyrrolidinemethanamine, N-[5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 662117-30-8 CAPLUS

CN 1,2-Benzenediamine, 4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-N2-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 662117-31-9 CAPLUS

CN Benzenamine, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 662117-33-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 662117-34-2 CAPLUS

CN Benzenamine, 5-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 662117-38-6 CAPLUS

CN 4-Morpholineethanamine, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 662117-40-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-bromo-7-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 662117-43-3 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyano- (9CI) (CA INDEX NAME)




RN 662117-44-4 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-43-3


CMF C20 H14 Br N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-45-5 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 662117-46-6 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-45-5


CMF C20 H14 Br N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-47-7 CAPLUS

CN 8-Quinolinesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 662117-48-8 CAPLUS

CN 8-Quinolinesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-47-7


CMF C22 H16 Br N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-49-9 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 662117-50-2 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-49-9


CMF C20 H17 Br N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-51-3 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)- (9CI) (CA INDEX NAME)




RN 662117-52-4 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-51-3


CMF C22 H18 Br N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 662117-54-6 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-91-1


CMF C17 H15 Br N6 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-55-7 CAPLUS


CN Benzenesulfonamide, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 662117-56-8 CAPLUS
 CN Benzenesulfonamide, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 662117-55-7
 CMF C19 H14 Cl2 N4 O3 S




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 662117-58-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[[2-(4-morpholinyl)ethyl]amino]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 662117-59-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-64-8 CAPLUS

CN Benzonitrile, 3,3'-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]imino]bis(methylene)]bis- (9CI) (CA INDEX NAME)



RN 662117-67-1 CAPLUS

CN Benzonitrile, 3-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 662117-68-2 CAPLUS

CN Benzonitrile, 3-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 662117-67-1

CMF C21 H16 Cl N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 662117-69-3 CAPLUS
CN Benzenesulfonamide, N-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano- (9CI) (CA INDEX NAME)



RN 662117-70-6 CAPLUS
CN Benzenesulfonamide, N-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 662117-69-3
CMF C20 H14 Cl N5 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 662117-71-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(1-

piperidinyloxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-72-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(1-piperidinyloxy)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-71-7


CMF C20 H23 Cl N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-91-1 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 662117-32-0, 6-Chloro-2-(4-fluoro-3-nitrophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazopyridines as Itk kinase inhibitors for use against

asthma and allergic rhinitis)

RN 662117-32-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-(4-fluoro-3-nitrophenyl)-7-methyl-
(9CI) (CA INDEX NAME)




IT 662117-27-3P, tert-Butyl (2R)-2-[[[4-(6-chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-hydroxyphenyl]amino]methyl]pyrrolidine-1-carboxylate 662117-29-5P, 6-Chloro-7-methyl-2-[4-[2-(morpholin-4-yl)ethoxy]-3-nitrophenyl]-3H-imidazo[4,5-b]pyridine 662117-36-4P, 6-Chloro-2-(4-nitrophenyl)-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine 662117-37-5P, 6,7-Dichloro-2-(4-nitrophenyl)-3H-imidazo[4,5-b]pyridine 662117-57-9P, 4-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)aniline 662117-60-4P, 6-Chloro-2-[4-(2-chloroethoxy)phenyl]-7-methoxy-3H-imidazo[4,5-b]pyridine 662117-61-5P, 2-[4-(6-Chloro-7-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethanol 662117-65-9P, 4-(6-Chloro-7-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)aniline 662117-66-0P, 6-Chloro-7-methoxy-2-(4-nitrophenyl)-3H-imidazo[4,5-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis)

RN 662117-27-3 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-hydroxyphenyl]amino]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 662117-29-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methyl-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 662117-36-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-(4-nitrophenyl)-N-phenyl-
 (9CI) (CA INDEX NAME)




RN 662117-37-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-(4-nitrophenyl)- (9CI) (CA
 INDEX NAME)




RN 662117-57-9 CAPLUS
 CN Benzenamine, 4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA
 INDEX NAME)




RN 662117-60-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-(2-chloroethoxy)phenyl]-7-methoxy-
 (9CI) (CA INDEX NAME)




RN 662117-61-5 CAPLUS
 CN Ethanol, 2-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 662117-65-9 CAPLUS
 CN Benzenamine, 4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 662117-66-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:466012 CAPLUS
 DOCUMENT NUMBER: 137:47228
 TITLE: Preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines as NPY5 receptor activity modulators

INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.;
 Brielmann, Harry L.; Darrow, James William; De
 Lombaert, Stéphane; Hutchison, Alan; Tran, Jennifer;
 Zheng, Xiaozhang; Elliott, Richard Louis; Hammond,
 Marlys
 PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.
 SOURCE: PCT Int. Appl., 134 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2002048152 | A2 | 20020620 | WO 2001-US47863 | 20011211 |
| WO 2002048152 | A3 | 20030508 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 200220276 | A | 20020624 | AU 2002-20276 | 20011211 |
| US 2003036652 | A1 | 20030220 | US 2001-13846 | 20011211 |
| US 6566367 | B2 | 20030520 | | |
| EP 1347982 | A2 | 20031001 | EP 2001-270536 | 20011211 |
| EP 1347982 | B1 | 20051116 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004520299 | T | 20040708 | JP 2002-549683 | 20011211 |
| BR 2001016113 | A | 20040803 | BR 2001-16113 | 20011211 |
| AT 310004 | T | 20051215 | AT 2001-270536 | 20011211 |
| ES 2249384 | T3 | 20060401 | ES 2001-1270536 | 20011211 |
| EP 1695977 | A2 | 20060830 | EP 2005-16735 | 20011211 |
| EP 1695977 | A3 | 20060920 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| US 2004072847 | A1 | 20040415 | US 2003-410648 | 20030409 |
| US 6943199 | B2 | 20050913 | | |
| MX 2003PA04245 | A | 20030922 | MX 2003-PA4245 | 20030514 |
| US 2005033048 | A1 | 20050210 | US 2003-415457 | 20030815 |
| US 2006040964 | A1 | 20060223 | US 2005-183615 | 20050718 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 2000-254990P | P 20001212 |
| | | | EP 2001-270536 | A3 20011211 |
| | | | US 2001-13846 | A3 20011211 |
| | | | WO 2001-US47863 | W 20011211 |
| | | | US 2003-410648 | A3 20030409 |

OTHER SOURCE(S): MARPAT 137:47228
 GI



AB Title compds. [I; X = O, H₂; A, D, V, W, Y, Z independently = N, CR₁; R₁ = H, halo, OH, NH₂, NO₂, CN, CONH₂, COOH; B = N, CR₂; E = CR₃; R₂, R₃ independently = H, halo, OH, NH₂, NO₂, CN, CONH₂, COOH; G = N, NH; J = NH, N; L = bond, CO; dotted bond = single, double] capable of modulating NPY₅ receptor activity are prepared Such compds. may be used to modulate ligand binding to NPY₅ receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and method for treating such disorders are provided, as are methods for using such compds. for detecting NPY₅ receptors.


IT 438191-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines as NPY₅ receptor activity modulators)

RN 438191-11-8 CAPLUS

CN Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one, 1'-(6-bromo-7-chloro-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

24.37

196.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.12

-3.12

STN INTERNATIONAL LOGOFF AT 20:40:42 ON 08 NOV 2007